FUNDAMENTALS · Fundamentals · US Healthcare

The Ensign Group (ENSG) Fundamentals 2026 — P/E 26.9x, Revenue Analysis | SniperIQ

The Ensign Group (ENSG) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of $9.9B, trading at

70.18 on the NASDAQ. This SniperIQ fundamentals page covers The Ensign Group's valuation (P/E 26.9x, P/B 4.2x), profitability (net margin 6.9%), revenue ($5.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$9.9B
P/E (TTM)26.9x
Net Margin6.9%
Revenue (FY25)$5.1B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is The Ensign Group's market cap?

The Ensign Group (ENSG) has a market capitalization of approximately $9.9B, trading at

70.18 on the NASDAQ. Market cap moves with the live share price.

What is The Ensign Group's P/E ratio?

The Ensign Group's trailing twelve-month P/E ratio is 26.9x, with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is The Ensign Group?

The Ensign Group runs a net profit margin of 6.9%, a gross margin of 13.9%, and an operating margin of 8.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does The Ensign Group generate?

The Ensign Group reported revenue of $5.1B for fiscal year 2025, with net income of

44M and earnings per share (EPS) of 6. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does The Ensign Group pay a dividend?

The Ensign Group offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is The Ensign Group financially healthy?

The Ensign Group carries a debt-to-equity ratio of 0.95x and a current ratio of 1.56x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is The Ensign Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For The Ensign Group (ENSG) the key facts are: market cap $9.9B, P/E 26.9x, revenue $5.1B, 52-week range 134.79-218. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track The Ensign Group's full fundamentals live

Get The Ensign Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Zhejiang Jolly Pharmaceutical (300181) fundamentals · Ningbo Menovo Pharmaceutical (603538) fundamentals · Krystal Biotech (KRYS) fundamentals · Autek China (300595) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons